VTRS FRAUD: Suffer Losses on Viatris Inc.? You may have been Affected by Fraud and are Urged to Contact BFA Law (NASDAQ:VTRS)

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational status and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until June 3, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint alleges that Viatris misrepresented its facilities as being in "good operating condition" and committed to high-quality manufacturing standards, despite a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has significantly impacted Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results, Viatris disclosed that the negative impact from the Indore facility's inspection would reduce 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price fell roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].